4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000950170-25-038216
Chief Executive Officer sold 14,435 shares at an average $42.70 ($616,349)
- Chief Executive Officer acquired 28,250 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Kulkarni Samarth · Chief Executive Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-03-10 | Exercise or conversion : show line 1 in the form | +19,250 | 190,863 | D | ||
| 2025-03-11 | Sale : show line 2 in the form | −9,973 | $42.42 | $423,055 | 180,890 | D |
| 2025-03-11 | Exercise or conversion : show line 3 in the form | +9,000 | 189,890 | D | ||
| 2025-03-12 | Sale : show line 4 in the form | −4,462 | $43.32 | $193,294 | 185,428 | D |
| Open-market sales · 14,435 sh · avg $42.70 · $616,349 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-03-10 | Exercise or conversion : show line 5 in the form Restricted Stock Units | −19,250 | 38,500 | D |
| 2025-03-11 | Exercise or conversion : show line 6 in the form Restricted Stock Units | −9,000 | 0 | D |
Loading xslF345X05/ownership.xml…